Overview
Rabin Martin helps health brands and organizations improve outcomes, access, and equity. They design and carry out strategies that unlock new markets for medicines and vaccines, then manage execution from planning to measurement. They combine global health expertise with commercial strategy, health system strengthening, and equity work to turn plans into real results in 80 markets, including work with UN agencies, pharma companies like J&J and Takeda, and foundations such as the Gates Foundation. Their approach pairs local market knowledge and partnerships with end-to-end delivery—strategy, solution development, implementation, and evaluation—to create impact for both public health and business growth. Their goal is to deliver lasting health improvements while helping clients grow their access and reach.
Work here?Claim your company
Simplify's take
What believers are saying
- Rabin Martin published October 22, 2026 global health security priorities with CDC and HHS leaders.
- Recent July 2026 reports on HTA and access signal active client demand.
- Jennifer Martin joined Climate Bonds Initiative in September 2026, showing senior-talent marketability.
What critics are saying
- Most clients are large global pharma companies, creating concentration risk and budget sensitivity.
- Jennifer Martin left in September 2026, signaling retention pressure on senior relationship builders.
- J&J or Takeda insourcing would erase marquee credibility and revenue by 2027.
What makes Rabin Martin unique
- Rabin Martin owns global health consulting, blending pharma commercialization with access and equity work.
- Its 2026 content targets HTA, LMIC access, and stakeholder engagement, not generic strategy.
- The firm cites 80 markets and $2 billion in health programming experience.
Help us improve and share your feedback! Did you find this helpful?